14-day Premium Trial Subscription Sign Up For FreeGet Free

Agios Pharmaceuticals Stock Forecast NASDAQ:AGIO

Price Target and Analyst Ratings

Most Recent Rating

On July 30, 2021 "SVB Leerink" gave "$50.00" rating for AGIO. The price target was set to $48.090.0%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-07-30 $50.00 Initiated by SVB Leerink $48.09 $48.090.0%
2021-07-30 $88.00 - $93.00 Target Raised by HC Wainwright $48.09 $49.84→0.3%
2021-07-30 $58.00 - $39.00 Downgraded by The Goldman Sachs Group $48.09 $49.84→0.3%
2021-06-30 Market Perform Initiated by Raymond James $55.11
2021-06-13 Hold Reiterated by Oppenheimer $57.74
2021-06-10 Buy Initiated by HC Wainwright $59.50 $88.00
2021-06-10 Buy Initiated by HC Wainwright $59.50
2021-05-06 Buy Target Raised by Canaccord Genuity $55.10 $57.00 → $65.00
2021-04-30 Positive - Overweight Target Raised by Barclays $55.80 $65.00 → $70.00
2021-04-30 Buy Target Raised by Canaccord Genuity $55.80 $57.00 → $65.00
2021-04-30 Neutral Initiated by The Goldman Sachs Group $55.80
2021-03-08 Overweight - Neutral Reiterated by JPMorgan Chase & Co. $48.31 $54.00
2021-03-04 Outperform - Market Perform Reiterated by SVB Leerink $47.33 $55.00 → $50.00
2021-03-01 Overweight - Neutral Downgraded by JPMorgan Chase & Co. $47.51 $64.00 → $54.00
2021-02-26 Outperform - Market Perform Downgraded by SVB Leerink $47.44 $55.00 → $50.00
2021-02-26 Outperform - Market Perform Downgraded by SVB Leerink $47.44
2021-01-27 Positive - Overweight Target Raised by Barclays $45.84 $58.00 → $65.00
2021-01-27 Outperform Target Raised by SVB Leerink $45.84 $51.00 → $55.00
2021-01-27 Positive - Overweight Reiterated by Barclays $45.84 $58.00 → $65.00
2021-01-14 Target Raised by Barclays $45.95 $50.00 → $58.00
2020-12-28 Buy Target Lowered by Canaccord Genuity $44.54 $70.00 → $57.00
2020-12-22 Target Lowered by SVB Leerink $41.85 $61.00 → $51.00
2020-12-22 Target Lowered by Royal Bank of Canada $41.85 $59.00 → $66.00
2020-12-21 Target Raised by Piper Sandler $42.62 $73.00 → $80.00
2020-12-09 Target Lowered by BMO Capital Markets $33.80 $57.00 → $50.00
2020-12-09 Outperform Target Lowered by SVB Leerink $33.80 $67.00 → $61.00
2020-11-20 Overweight Target Raised by Barclays $43.59 $46.00 → $50.00
2020-11-19 Overweight Target Raised by Cantor Fitzgerald $41.79 $68.00 → $79.00
2020-10-22 Equal Weight - Overweight Upgraded by Barclays $38.87 $46.00
2020-10-19 Buy Target Lowered by Needham & Company LLC $35.28 $71.00 → $69.00
2020-10-19 Positive - Outperform Target Lowered by SVB Leerink $35.28 $72.00 → $67.00
2020-10-19 Buy Reiterated by Canaccord Genuity $35.28 $70.00
2020-10-19 Overweight Target Lowered by Piper Sandler $35.28 $80.00 → $73.00
2020-07-31 Overweight Target Raised by Cantor Fitzgerald $45.32 $70.00 → $72.00
2020-07-31 Buy Reiterated by Canaccord Genuity $45.32 $72.00
2020-07-30 Buy Initiated by Needham & Company LLC $47.45 $71.00
2020-06-15 Hold Reiterated by Oppenheimer $48.30
2020-06-15 Outperform Target Raised by SVB Leerink $48.30 $70.00 → $72.00
2020-06-15 Buy Target Raised by Citigroup $48.30 $64.00 → $75.00
2020-06-15 Buy Target Raised by Guggenheim $48.30 $60.00 → $66.00
2020-06-12 Overweight Target Raised by Piper Sandler $47.14 $70.00 → $80.00
2020-05-04 Overweight Target Raised by JPMorgan Chase & Co. $38.40 $72.00 → $82.00
2020-05-01 Buy Reiterated by Canaccord Genuity $37.01 $72.00
2020-04-30 Hold Reiterated by Oppenheimer $41.14
2020-04-30 Buy Reiterated by Needham & Company LLC $41.14 $71.00

AGIO Stock Trend

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $48.05 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -20.30% during the next 3 months and, with a 90% probability hold a price between $29.23 and $38.29 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-30 $36.48 $42.17 $47.85
2021-10-01 $36.29 $41.97 $47.66
2021-10-04 $36.09 $41.78 $47.46
2021-10-05 $35.90 $41.58 $47.27
2021-10-06 $35.70 $41.39 $47.07
2021-10-07 $35.51 $41.20 $46.88
2021-10-08 $35.32 $41.00 $46.69
2021-10-11 $35.12 $40.81 $46.49
2021-10-12 $34.93 $40.61 $46.30
2021-10-13 $34.73 $40.42 $46.10
2021-10-14 $34.54 $40.22 $45.91
2021-10-15 $34.34 $40.03 $45.71
2021-10-18 $34.15 $39.84 $45.52
2021-10-19 $33.96 $39.64 $45.33
2021-10-20 $33.76 $39.45 $45.13
2021-10-21 $33.57 $39.25 $44.94
2021-10-22 $33.37 $39.06 $44.74
2021-10-25 $33.18 $38.86 $44.55
2021-10-26 $32.99 $38.67 $44.36
2021-10-27 $32.79 $38.48 $44.16
2021-10-28 $32.60 $38.28 $43.97
2021-10-29 $32.40 $38.09 $43.77
2021-11-01 $32.21 $37.89 $43.58
2021-11-02 $32.01 $37.70 $43.38
2021-11-03 $31.82 $37.50 $43.19
2021-11-04 $31.63 $37.31 $43.00
2021-11-05 $31.43 $37.12 $42.80
2021-11-08 $31.24 $36.92 $42.61
2021-11-09 $31.04 $36.73 $42.41
2021-11-10 $30.85 $36.53 $42.22

About Agios Pharmaceuticals

Agios Pharmaceuticals Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic maligna... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT